A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- William Schelman, MD, PhD
HUTCHMED International Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
153 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Integrated Clinical Oncology Network Pty Ltd (icon)
Brisbane, Queensland, Australia
- Flinders Medical Centre
Adelaide, South Australia, Australia
- the Queen Elizabeth Hospital
Adelaide, South Australia, Australia
- Austin Hopistal Medical Oncology Unit
Melbourne, Victoria, Australia
- Monash Health
Melbourne, Victoria, Australia
- Western Health
Melbourne, Victoria, Australia
- Ordensklinikum Linz Barmherzige Schwestern
Linz, AUT, Austria
- Schwerpunktkrankenhaus Feldkirch
Rankweil, AUT, Austria
- Klinikum Steyr
Steyr, AUT, Austria
- Wiener Gesundheitsverbund - Klinik Ottakring
Vienna, AUT, Austria
- Klinikum Wels-Grieskirchen Gmbh
Wels, AUT, Austria
- Landesklinikum Wiener Neustadt
Wiener Neustadt, AUT, Austria
- Onze-Lieve-Vrouwziekenhuis Olv - Campus Aalst
Aalst, BEL, Belgium
- Ucl St-Luc
Brussels, BEL, Belgium
- Grand Hopital de Charleroi
Charleroi, BEL, Belgium
- Uz Antwerpen
Edegem, BEL, Belgium
- Centres Hospitaliers Jolimont
Haine-Saint-Paul, BEL, Belgium
- Uz Leuven
Leuven, BEL, Belgium
- Az Delta Roeselare
Roeselare, BEL, Belgium
- Az Turnhout
Turnhout, BEL, Belgium
- Chu Mont-Godinne
Yvoir, BEL, Belgium
- Chu de Lige - Domaine Universitaire Du Sart Tilman
Liège, Wallonia, Belgium
- Clinique Chc Montlegia
Liège, Wallonia, Belgium
- Masaryk Memorial Cancer Institute, Hematoonkologie
Brno, Moravia, Czechia
- Fakultni Nemocnice Olomouc, Onkologicka Klinika
Olomouc, Moravia, Czechia
- Vseobecna Fakultni Nemocnice Vfn, Onkologicka Klinika
Prague, Czechia
- East Tallinn Central Hospital Centre of Oncology
Tallinn, Harju, Estonia
- Sihtasutus Pohja-Eesti Regionaalhaigla (perh) (north Estonia Medical Centre)
Tallinn, Harju, Estonia
- Tartu University Hospital Clinic of Haematology and Oncology
Tartu, Estonia
- Institut Bergonie
Bordeaux, FRA, France
- Unicancer
Caen, FRA, France
- Centre Georges-Francois Leclerc
Dijon, FRA, France
- Icm-Val D'Aurelle
Montpellier, FRA, France
- Hopital Pitie Salptriere
Paris, FRA, France
- Hopital St Antoine
Paris, FRA, France
- Saint-Louis Hospital
Paris, FRA, France
- Chu Poitiers
Poitiers, FRA, France
- Centre Hospitalier Annecy Genevois
Pringy, FRA, France
- Centre Hospitalier Universitaire Chu de Rennes - Hopital de Pontchaillou
Rennes, FRA, France
- Institut de Cancerologie Strasbourg-Europe
Strasbourg, FRA, France
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Aug 2020
- Primary completion
- 29 Jul 2022
- Completion
- 24 Apr 2024
- Last update posted
- 4 Apr 2025
- Registered enrollment
- 691
- Registry id
- NCT04322539
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.